Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares rose in premarket trading following the company's disclosure of expanded insurance coverage for TONMYA, its recently approved fibromyalgia treatment for adults. The firm announced a second agreement with a leading group purchasing organization, effective June 1, 2026, that adds access to approximately 17 million additional commercial lives in the United States.
With this second arrangement in place, TONMYA now carries commercial coverage for about 52 million U.S. lives, representing roughly 29% of the estimated 177 million commercial lives in the country. The company had previously announced an initial commercial coverage agreement on May 6, 2026, which provided access to approximately 35 million commercial lives.
TONMYA is approved by the U.S. Food and Drug Administration as the first new fibromyalgia medicine for adults in over 15 years. The product is a cyclobenzaprine HCl sublingual tablet intended for nightly dosing at bedtime and for longer-term use.
In addition to the changes in commercial coverage, Tonix said TONMYA is now available under Medicaid in most states, accounting for roughly 75 million Medicaid lives in total. The company also noted that discussions with Medicare regarding coverage are ongoing.
Tonix Pharmaceuticals is identified as a commercial-stage biotechnology company headquartered in Berkeley Heights, New Jersey. The recent coverage developments mark a step in the product's payer adoption trajectory, increasing the population with potential access through commercial plans and expanding the therapy's presence in publicly funded insurance programs.
Key details from the company's announcements include the effective date of June 1, 2026 for the second group purchasing organization agreement, the prior May 6, 2026 announcement covering about 35 million commercial lives, and the stated availability under Medicaid in most states covering about 75 million lives. The company said Medicare talks continue but provided no further specifics on timing or terms.
The information in this article is presented based on the company's disclosure and the coverage figures provided. Where specifics were not disclosed, the company indicated ongoing discussions rather than finalized agreements.